The seroepidemiology of Bordetella pertussis infection in Western Europe
The seroepidemiology of Bordetella pertussis infection in Western Europe
复制标题
DOI：
10.1017/s0950268804003012
复制
发表时间：
2005-02-01
影响因子：
4.2
通讯作者：
Miller, E
中科院分区：
文献类型：
--
作者：
Pebody, RG;Gay, NJ;Miller, E
高滴度的百日咳毒素（PT）抗体已被证明是预测近期感染百日咳博德特氏菌。1994年至1998年期间，在6个西欧国家测定了标准化抗PT抗体的血清阳性率，并与历史监测和疫苗方案数据相关。计算一系列全细胞和无细胞百日咳疫苗试验的标准化抗PT滴度。在血清学调查中，高滴度血清（> 125单位/毫升）分布在高覆盖率（> 90%）和低覆盖率（<90%）国家的所有年龄组。与其他国家（荷兰，0.5%;芬兰，0%）相比，在其主要项目中使用高滴度生产疫苗的国家（意大利，11.5%;西德国，13.3%;法国，4.3%;东德国，4.0%）的婴儿更可能出现高滴度血清。在高覆盖率国家（芬兰、荷兰、法国、东德国），青少年（10-19岁）和成人近期感染的可能性明显更高，而在低覆盖率国家（<90%;意大利、西德国、联合王国），儿童（3-9岁）感染的可能性高于青少年。在这些调查之后引入的旨在通过加速初级接种计划或为年龄较大的儿童和青少年接种加强剂来保护婴儿免受严重疾病的方案变化的影响和作用可以用这种方法进行评估。
High titres of pertussis toxin (PT) antibody have been shown to be predictive of recent infection with Bordetella pertussis. The seroprevalence of standardized anti-PT antibody was determined in six Western European countries between 1994 and 1998 and related to historical surveillance and vaccine programme data. Standardized anti-PT titres were calculated for a series of whole-cell and acellular pertussis vaccine trials. For the serological surveys, high-titre sera (> 125 units/ml) were distributed throughout all age groups in both high- (> 90 %) and low-coverage (< 90 %) countries. High-titre sera were more likely in infants in countries using high-titre-producing vaccines in their primary programme (Italy, 11.5 %; Western Germany, 13.3 %; France, 4.3 %; Eastern Germany, 4.0 %) compared to other countries (The Netherlands, 0.5 %; Finland, 0 %). Recent infection was significantly more likely in adolescents (10-19 years old) and adults in high-coverage countries (Finland, The Netherlands, France, East Germany), whereas infection was more likely in children (3-9 years old) than adolescents in low-coverage (< 90 %; Italy, West Germany, United Kingdom) countries. The impact and role of programmatic changes introduced after these surveys aimed at protecting infants from severe disease by accelerating the primary schedule or vaccinating older children and adolescents with booster doses can be evaluated with this approach.